SUNNYVALE, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- Cepheid will announce financial results for the first quarter 2008 after the markets close on Thursday, May 1, 2008. The announcement will be followed by a live conference call and webcast that afternoon at 4:30 p.m. Eastern Time.
John Bishop, Chief Executive Officer, Andy Miller, Senior Vice President, Chief Financial Officer and Michael Myhre, Vice President, Corporate Controller, will host the conference call to discuss Cepheid’s financial results and business highlights. David Persing M.D., Ph.D., Executive Vice President and Chief Medical and Technology Officer, and Robert Koska, Senior Vice President Worldwide Commercial Operations, will also participate in the Q-and-A portion of the call.
Interested participants and investors may access the teleconference call by dialing 888-679-8018 (U.S./Canada) or 617-213-4845 (international), participant code 93009314. A telephonic replay will be available for seven days beginning at 6:30 p.m. Eastern Time. Access numbers for this replay are 888-286-8010 (U.S./Canada) and 617-801-6888 (international); participant code 25802805. Callers can also pre-register for the call through the following link: https://www.theconferencingservice.com/prereg/key.process?key=PYWVXBAML
The webcast of the call can be accessed on the Investor section of Cepheid’s Web site at http://www.cepheid.com under Investors: Events: Webcasts and Presentations. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download, and install any necessary software. After the live webcast, a replay will remain available in the Investors section of Cepheid’s Web site for 90 days.
About Cepheid
Based in Sunnyvale, Calif., Cepheid is an on-demand molecular diagnostics company that develops, manufactures, and markets fully- integrated systems for genetic analysis in the clinical, industrial and biothreat markets. The company’s systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company’s easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See http://www.cepheid.com for more information.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080129/LATU101LOGO)
CONTACT: Company, John L. Bishop, CEO, +1-408-541-4191,
john.bishop@cepheid.com, or Jared Tipton, Director, IR & Corporate
Communications, +1-408-400-8377, jared.tipton@cepheid.com, both of Cepheid;
or Media, Chris Stamm of Schwartz Communications, +1-781-684-0770,
cepheid@schwartz-pr.com; or Investors, Jason Spark of Porter Novelli Life
Sciences, +1-619-849-6005, jspark@pnlifesciences.com, both for Cepheid
Web site: http://www.cepheid.com/
